Atossa Genetics Inc. (ATOS) Analysts See $-0.07 EPS

February 15, 2018 - By Adrian Erickson

Analysts expect Atossa Genetics Inc. (NASDAQ:ATOS) to report $-0.07 EPS on March, 15.They anticipate $0.70 EPS change or 90.91 % from last quarter’s $-0.77 EPS. After having $-0.17 EPS previously, Atossa Genetics Inc.’s analysts see -58.82 % EPS growth. The stock decreased 5.74% or $0.0413 during the last trading session, reaching $0.6776. About 8.44M shares traded or 79.34% up from the average. Atossa Genetics Inc. (NASDAQ:ATOS) has declined 86.91% since February 15, 2017 and is downtrending. It has underperformed by 103.61% the S&P500.

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company has market cap of $21.56 million. The firm is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions. It currently has negative earnings. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as makes and sells various medical devices primarily consisting of tools to assist breast surgeons.

More important recent Atossa Genetics Inc. (NASDAQ:ATOS) news were published by: Globenewswire.com which released: “Atossa Genetics Presents Additional Findings from its Phase 1 Study of Oral …” on February 01, 2018, also Globenewswire.com published article titled: “Atossa Genetics to Present at Adoptive T-Cell Therapy Symposium – Molecular …”, Seekingalpha.com published: “Atossa Genetics: Wait And See” on February 11, 2018. More interesting news about Atossa Genetics Inc. (NASDAQ:ATOS) was released by: Globenewswire.com and their article: “Atossa Genetics to Host Conference Call to Present Additional Findings from …” with publication date: January 31, 2018.